Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are two stocks where Wall Street’s pessimism is creating a buying opportunity and one where the outlook is warranted.
One Stock to Sell:
G-III (GIII)
Consensus Price Target: $28.40 (5.8% implied return)
Founded as a small leather goods business, G-III (NASDAQ: GIII) is a fashion and apparel conglomerate with a diverse portfolio of brands.
Why Should You Dump GIII?
- Products and services have few die-hard fans as sales have declined by 1.2% annually over the last two years
- Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment
- Below-average returns on capital indicate management struggled to find compelling investment opportunities
G-III is trading at $26.85 per share, or 11.8x forward P/E. Check out our free in-depth research report to learn more about why GIII doesn’t pass our bar.
Two Stocks to Buy:
Hubbell (HUBB)
Consensus Price Target: $481.27 (2.4% implied return)
A respected player in the electrical segment, Hubbell (NYSE: HUBB) manufactures electronic products for the construction, industrial, utility, and telecommunications markets.
Why Do We Love HUBB?
- Operating margin expanded by 7.6 percentage points over the last five years as it scaled and became more efficient
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 18.1% exceeded its revenue gains over the last five years
- Free cash flow margin expanded by 5.9 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $470 per share, Hubbell trades at 24.1x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.
Natera (NTRA)
Consensus Price Target: $202.50 (1.8% implied return)
Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.
Why Will NTRA Beat the Market?
- Products are reaching more customers as its tests processed averaged 21% growth over the past two years
- Adjusted operating profits increased over the last two years as the company gained some leverage on its fixed costs and became more efficient
- Free cash flow turned positive over the last five years, indicating the company has passed a significant test
Natera’s stock price of $199 implies a valuation ratio of 12.3x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.
Stocks We Like Even More
Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
